Clinical trials: Venous Thromboembolic Event
Pulmonary Embolism
Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 3 ("RETRIEVE 3")
The purpose of this study is to determine if the Crux Vena Cava Filter System is safe and effective in preventing pulmonary embolism.
- Trial name
- RETRIEVE 3 (NCT01120522)
- Testing
- Inferior Vena Cava Filter
- Where
- 2 sites in Belgium
- Volunteers
- 17 people
- Sponsor
- Crux Biomedical
Venous Thromboembolism
Retrospective Study to Review Patients at Risk for VTE at Hospital Discharge
An investigator initiated study exploring VTE prophylaxis at the time of hospital discharge.
- Trial name
- NCT00604370
- Volunteers
- 2,500 people
- Sponsor
- Brigham and Women's Hospital
Venous Thromboembolism, Pulmonary Embolism
Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage
The objective of this randomized clinical trial is to evaluate the safety and efficiency of different anticoagulation schemes with heparin for venous thromboembolism prevention in patients with hypertensive intracerebral…
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, Intracerebral Hemorrhage, Deep Vein Thrombosis
- Trial name
- NCT06753786
- Testing
- Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting within the first 2 days but not earlier than 12 hours after a hospital admission., Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting on the 3rd day after a hospital admission.
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Pirogov Russian National Research Medical University
Venous Thromboembolism
Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)
Hospitalized medical patients have an increased risk of venous thromboembolism (VTE) across the continuum of care, including after hospital discharge.
- Trial name
- DC-eALERT (NCT03728166)
- Testing
- Electronic alert
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
Venous Thromboembolism
Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism
Prospective, multicenter observational study, of the effectiveness of a standard of care protocol implemented to enhance home treatment of VTE.
- Trial name
- MATHVTE (NCT03404635)
- Testing
- Apixaban, Rivaroxaban
- Where
- 2 sites in United States
- Volunteers
- 1,300 people
- Sponsor
- Indiana University
Venous Thrombosis (Disorder)
Patient Education Bundle vs. Nurses Feedback and Coaching to Prevent Missed Doses of VTE Prophylaxis
VTE associated harm is underappreciated among hospitalized patients and may be associated with missed doses of VTE prophylaxis medications.
- Trial name
- ENACT (NCT03367364)
- Testing
- Patient education bundle (PEB),, Nurse feedback and coaching (NFC)
- Where
- United States
- Volunteers
- 9,657 people
- Sponsor
- Johns Hopkins University
Venous Thromboembolism
Statin Use in Patients With Acute VTE
This is a pilot, randomized, open-labelled study. Eligible patients will be enrolled and randomized 1:1 into "anticoagulation" arm or "anticoagulation plus atorvastatin" arm, with atorvastatin given at 40 mg orally daily for 3…
- Trial name
- NCT02331095
- Testing
- Atorvastatin, Anticoagulation Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University
Obesity, Obesity, Morbid
Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis
Pregnant and recently postpartum women are at significantly higher risk of developing a blood clot in their arms or legs known as a deep venous thrombosis (DVT) and/or a blood clot in their lungs known as a pulmonary embolism…
- Conditions
- Obesity, Obesity, Morbid, Pregnancy, Complications; Cesarean Section
- Trial name
- NCT02070237
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- MemorialCare Health System
Anticoagulants, Atrial Fibrillation
Improving Anticoagulation Control in VISN 1
Over 100,000 VHA patients receive anticoagulants (blood thinners) each year to prevent blood clots (including strokes). Too much anticoagulation increases the risk of serious or even fatal bleeding, and too little anticoagulation…
- Conditions
- Anticoagulants, Atrial Fibrillation, Venous Thromboembolism
- Trial name
- NCT01653405
- Testing
- Multifaceted behavioral intervention
- Where
- United States
- Volunteers
- 1,260,576 people
- Sponsor
- VA Office of Research and Development
Deep Vein Thrombosis, Venous Thrombosis
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic…
- Conditions
- Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism
- Trial name
- ATTRACT (NCT00790335)
- Testing
- Recombinant tissue plasminogen activator (rt-PA)
- Where
- 56 sites in United States
- Volunteers
- 692 people
- Sponsor
- Washington University School of Medicine
Arrhythmia, Atrial Fibrillation
Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)
To determine the benefits and risks of oral anticoagulant therapy in reducing embolic stroke and systemic emboli in patients with atrial fibrillation without rheumatic heart disease.
- Conditions
- Arrhythmia, Atrial Fibrillation, Cardiovascular Diseases, Cerebral Embolism and Thrombosis
- Trial name
- NCT00000517
- Testing
- warfarin
- Sponsor
- Massachusetts General Hospital
Venous Thromboembolism, Deep Venous Thrombosis
Rate of Venous Thrombosis in Acutely Ill Patients Hospitalized in Internal Medicine Wards
After reports from observational studies suggesting an association between acutely ill medical patients and venous thromboembolism (VTE), interventional trials with anticoagulants drugs have demonstrated a significant reduction…
- Trial name
- AURELIO (NCT03157843)
- Testing
- low-molecular-weight heparin
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- University of Roma La Sapienza
Pulmonary Embolism, Venous Thromboembolic Disease
Prospective, Multi-center, Single-arm Study to Assess the Safety of Retrieval of the Recovery G2 Filter.
This study was designed to assess the safety of retrieval of the Bard Recovery® G2® Filter System. The G2 filter is an FDA-cleared device for inferior vena caval interruption in patients with pulmonary thromboembolism.
- Trial name
- EVEREST (NCT00556426)
- Testing
- Bard Recovery G2 Filter System
- Volunteers
- 100 people
- Sponsor
- C. R. Bard
Venous Thromboembolism, Pulmonary Embolism
Epidemiology of Venous Thromboembolism
More than 5 years ago the DVT FREE Registry was conceived. Its database consists of 5,451 ultrasound-confirmed DVT patients from 183 institutions.
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, Cancer, Deep Vein Thrombosis
- Trial name
- NCT00456196
- Where
- United States
- Volunteers
- 5,451 people
- Sponsor
- Brigham and Women's Hospital
Placental Vascular Pathologies, Venous Thromboembolism Diseases
Prediction of the Risk of Placental Vascular Pathology and Venous Thromboembolic Disease
Venous thromboembolic (VTE) disease is the first cause of maternal mortality in the world. Some other pregnancy pathologies called Placental Vascular Pathologies (PVP) are linked to VTE by biological thrombophilia and are the…
- Trial name
- AngioPred (NCT00695942)
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Venous Thromboembolism
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
Rationale: After total knee arthroplasty (TKA) surgery, patients are at risk to develop venous thromboembolism (VTE) or deep venous thrombosis (DVT) potentially resulting in a fatal pulmonary embolism (PE).
- Trial name
- DARINA (NCT01431456)
- Testing
- Dabigatran, Rivaroxaban, Nadroparin
- Where
- Netherlands
- Volunteers
- 148 people
- Sponsor
- Martini Hospital Groningen
COVID-19, Venous Thromboses
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
This study is being conducted to assess the effectiveness of intermediate versus prophylactic doses of anticoagulation (blood thinners) in patients critically ill with COVID-19 in the intensive care units (ICUs) throughout the…
- Conditions
- COVID-19, Venous Thromboses, Arterial Thrombosis
- Trial name
- IMPROVE (NCT04367831)
- Testing
- Enoxaparin Prophylactic Dose, Heparin Infusion, Heparin SC
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Columbia University
Deep Vein Thrombosis (DVT)
Improving Emergency Department Testing for Deep Vein Thrombosis
This observational study will use a new way to test for deep vein thrombosis (DVT) of the leg. A DVT is a blood clot in the leg and is a medical problem that can cause swelling, pain, and redness.
- Trial name
- NCT06195787
- Where
- Canada
- Volunteers
- 458 people
- Sponsor
- Dr. Kerstin de Wit
Venous Thromboembolism
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'.
- Trial name
- ROXI-CATH (NCT06299111)
- Testing
- REGN9933, REGN7508
- Where
- 23 sites in United States, Bulgaria and 4 more
- Volunteers
- 195 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thromboembolism
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
- Trial name
- NCT00329628
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 215 sites in United States, Argentina and 26 more
- Volunteers
- 4,541 people
- Sponsor
- Bayer